

Notice of Allowability	Application No.	Applicant(s)	
	10/725,440	OKADA, YUJI	
	Examiner	Art Unit	
	Robert Sellers	1712	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to the amendment filed May 18, 2006.
2. ☒ The allowed claim(s) is/are 1-5.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|--|
| <ol style="list-style-type: none"> 1. <input type="checkbox"/> Notice of References Cited (PTO-892) 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | <ol style="list-style-type: none"> 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____ 7. <input type="checkbox"/> Examiner's Amendment/Comment 8. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance 9. <input type="checkbox"/> Other _____ |
|---|--|

Art Unit: 1712

The following is an examiner's statement of reasons for allowance:

1. Withdrawn claim 4 has been reinstated.
2. The limitation of the hardening agent to an acid anhydride overcomes the 35 U.S.C. 112, first paragraph, rejection.
3. The claimed phosphonium compound of formula (I) wherein the group of formula (II) when m is 1, is confined to any one of R¹ to R⁴ and any one of R⁵ to R⁷ combined to form an alkylene group structured as a heterocyclic ring with two phosphorus atoms precludes the p-(xylenebis(triphenylphosphonium tetraphenyl borate) in the closest prior art of Ogata et al. Patent No. 3,637,572. The -CH₂-phenyl-CH₂-P⁺(phenyl)₃ moiety conforms to general formula (II) when m is 1 without forming a heterocyclic ring with two phosphorus atoms as newly claimed in the amendment filed May 19, 2006.
4. Phosphonium compounds (a) and (b) of claim 2 require m to be zero, thereby precluding the phosphonium compound of Ogata et al. wherein m is 1. Phosphonium compound (c) (formerly phosphonium compound (d)) of claim 2 defines R⁵ of formula (II) constituting R² of formula (I) to be combined with R¹ of formula (I) to form a C₁₋₈ alkylene group, thereby excluding the phenyl group of the phosphonium compound of Ogata et al. The phosphonium compound of Ogata et al. is embraced by former phosphonium compound (c) which has been deleted.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled

"Comments on Statement of Reasons for Allowance."

(571) 272-1093 (Fax No. (571) 273-8300 Monday to Friday, 9:30 to 6:00 rs 5/25/2006



ROBERT E.L. SELLERS
PRIMARY EXAMINER